Awale, Guleid M.
Barajaa, Mohammed A.
Kan, Ho-Man
Lo, Kevin W.-H.
Laurencin, Cato T. http://orcid.org/0000-0001-6765-3047
Article History
Received: 15 December 2021
Revised: 25 May 2022
Accepted: 29 May 2022
First Online: 5 July 2022
Declarations
:
: Dr. Cato T. Laurencin is the editor-in-chief and Dr. Kevin Lo is the assistant managing editor of <i>Regenerative Engineering and Translational Medicine</i>. Dr. Cato Laurencin has the following competing financial interests: Mimedx, Alkermes Company, Biobind, Soft Tissue Regeneration/Biorez, and Healing Orthopaedic Technologies-Bone. The authors have no non-financial competing interests.